 |
The Journal of Neuroscience, June 15, 2003, 23(12):5131-5140
Previous Article | Next Article 
Human Embryonic Germ Cell Derivatives Facilitate Motor Recovery of Rats with Diffuse Motor Neuron Injury
Douglas A. Kerr,1
Jerònia Lladó,1
Michael J. Shamblott,2
Nicholas J. Maragakis,1
David N. Irani,1
Thomas O. Crawford,1
Chitra Krishnan,1
Sonny Dike,1
John D. Gearhart,2 and
Jeffrey D. Rothstein1
Departments of 1Neurology and 2Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287
We have investigated the potential of human pluripotent cells to restore function in rats paralyzed with a virus-induced motor neuronopathy. Cells derived from embryonic germ cells, termed embryoid body-derived (EBD) cells, introduced into the CSF were distributed extensively over the rostrocaudal length of the spinal cord and migrated into the spinal cord parenchyma in paralyzed, but not uninjured, animals. Some of the transplanted human cells expressed the neuroglial progenitor marker nestin, whereas others expressed immunohistochemical markers characteristic of astrocytes or mature neurons. Rare transplanted cells developed immunoreactivity to choline acetyltransferase (ChAT) and sent axons into the sciatic nerve as detected by retrograde labeling. Paralyzed animals transplanted with EBD cells partially recovered motor function 12 and 24 weeks after transplantation, whereas control animals remained paralyzed. Semi-quantitative analysis revealed that the efficiency of neuronal differentiation and extension of neurites could not account for the functional recovery. Rather, transplanted EBD cells protected host neurons from death and facilitated reafferentation of motor neuron cell bodies. In vitro, EBD cells secrete transforming growth factor- (TGF- ) and brain-derived neurotrophic factor (BDNF). Neutralizing antibodies to TGF- and to BDNF abrogated the ability of EBD-conditioned media to sustain motor neuron survival in culture, whereas neutralizing antibodies to BDNF eliminated the axonal outgrowth from spinal organotypics observed with direct coculture of EBD cells. We conclude that cells derived from human pluripotent stem cells have the capacity to restore neurologic function in animals with diffuse motor neuron disease via enhancement of host neuron survival and function.
Key words: motor neuron disease; Sindbis virus; stem cells; embryonic germ cell; trophic factors; embryoid body
Received Jan. 15, 2003;
revised Mar. 28, 2003;
accepted Mar. 31, 2003.
This article has been cited by other articles:

|
 |

|
 |
 
O. Einstein and T. Ben-Hur
The Changing Face of Neural Stem Cell Therapy in Neurologic Diseases
Arch Neurol,
April 1, 2008;
65(4):
452 - 456.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Turnpenny, C. M. Spalluto, R. M. Perrett, M. O'Shea, K. P. Hanley, I. T. Cameron, D. I. Wilson, and N. A. Hanley
Evaluating Human Embryonic Germ Cells: Concord and Conflict as Pluripotent Stem Cells
Stem Cells,
February 1, 2006;
24(2):
212 - 220.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Wobus and K. R. Boheler
Embryonic Stem Cells: Prospects for Developmental Biology and Cell Therapy
Physiol Rev,
April 1, 2005;
85(2):
635 - 678.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Darman, S. Backovic, S. Dike, N. J. Maragakis, C. Krishnan, J. D. Rothstein, D. N. Irani, and D. A. Kerr
Viral-Induced Spinal Motor Neuron Death Is Non-Cell-Autonomous and Involves Glutamate Excitotoxicity
J. Neurosci.,
August 25, 2004;
24(34):
7566 - 7575.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Harper, C. Krishnan, J. S. Darman, D. M. Deshpande, S. Peck, I. Shats, S. Backovic, J. D. Rothstein, and D. A. Kerr
Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats
PNAS,
May 4, 2004;
101(18):
7123 - 7128.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
The Neuroscientist Comments
Neuroscientist,
December 1, 2003;
9(6):
427 - 429.
[PDF]
|
 |
|

|
 |

|
 |
 
G. Q. Daley, M. A. Goodell, and E. Y. Snyder
Realistic Prospects for Stem Cell Therapeutics
Hematology,
January 1, 2003;
2003(1):
398 - 418.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|